Baltimore, MD Clinical Trials Report — April 2026

For Baltimore residents exploring clinical trial options, April 2026 presents a critical window to participate in studies nearing their enrollment deadlines. A total of 115 trials across Baltimore are set to close within the next 90 days, with 29 of these actively seeking healthy volunteers. Individuals interested in contributing to medical advancements should explore these options promptly.

Urgent Opportunities: Trials Closing Soon

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on neurological conditions, cancer, and chronic pain are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Stroke (4 trials)
• Breast cancer (3 trials)
• Alzheimer disease (3 trials)
• Disability physical (3 trials)
• Mild cognitive impairment (3 trials)
• Parkinson disease (2 trials)
• Pain (2 trials)
• Quality of life (2 trials)
• Chronic pancreatitis (2 trials)
• Endometriosis (2 trials)

This month, Baltimore saw the opening of 15 new clinical trials, an increase from the 11 trials that launched in March 2026. This brings the city's total to 1,455 clinical trials currently recruiting across 530 research facilities, solidifying Baltimore's role as a significant hub for medical research in Maryland.

New Research Opportunities in April

April brings several notable new trials to Baltimore, offering participants the chance to engage with cutting-edge research across a range of health and behavioral challenges. These studies are sponsored by leading academic institutions, reflecting the strong research presence in the city.

• The University of Maryland, Baltimore is sponsoring NCT07532564, "Risk Factors, Costs, and Impacts of ED Boarding." This observational study, aiming for 30,486 participants, seeks to understand the factors, expenses, and operational effects of emergency department boarding, where admitted patients await placement on an inpatient floor.
• Johns Hopkins Bloomberg School of Public Health is leading two significant studies:
  • NCT07533877, "Testing Ultra-processed Warning Labels in United States." This randomized controlled online experiment, designed for 7,000 participants, will evaluate if adding an ultra-processed food (UPF) warning label to the FDA's proposed Nutrition Information Box changes consumer perceptions among U.S. adults.
  • NCT07536126, "Testing Non-Nutrition Menu Labels on Food Selections." This study, also for 7,000 participants, aims to test how environmental harm menu label designs affect the healthfulness of consumers' fast-food meal choices through hypothetical online ordering tasks.
• UNC Lineberger Comprehensive Cancer Center is sponsoring NCT07520188, "C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States." This project, involving 3,603 participants, aims to improve access to cervical cancer screening for women with Human Immunodeficiency Virus (HIV) receiving care at U.S.-based CASCADE clinical sites.
• Johns Hopkins Bloomberg School of Public Health is also sponsoring NCT07513337, "Effects of Cannabis Species Labeling and Marketing on Perceptual, Subjective and Objective Use Outcomes (Aim 2 Study)." This study, for 2,000 participants, investigates how cannabis product label and marketing claims influence perceptions, expectancies, and intentions among cannabis users.
• Johns Hopkins University is sponsoring NCT07540000, "The INTERvening for LUNG Health Trial." This Phase 4 research study, involving 800 participants, is being conducted to determine if a community health volunteer-delivered program can improve lung health for individuals at risk of chronic respiratory diseases in Bhaktapur, Nepal.

New trials this month are exploring a range of conditions, including asthma (diagnosis), brain cancer, brain stem stroke, cannabis use, cervical cancer, cervical precancer, chest pain, cognitive impairment, community acquired pneumonia (CAP), and consumer behavior. Behavioral trials account for the largest share of new studies with 7 new trials, followed by 3 device trials and 3 drug trials.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 15 new trials launched this month, 6 are actively seeking healthy volunteers. Across Baltimore, a total of 224 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Baltimore's Leading Research Institutions

Baltimore is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Johns Hopkins University (153 trials)
• Johns Hopkins Hospital (117 trials)
• Johns Hopkins University/Sidney Kimmel Cancer Center (73 trials)
• University of Maryland (59 trials)
• University of Maryland/Greenebaum Cancer Center (56 trials)
• Sinai Hospital of Baltimore (54 trials)
• University of Maryland Medical Center (49 trials)
• Research Site (47 trials)
• Johns Hopkins University School of Medicine (40 trials)
• Johns Hopkins (40 trials)
• Johns Hopkins School of Medicine (32 trials)
• Kennedy Krieger Institute (30 trials)

These institutions offer a broad spectrum of research, from oncology at Johns Hopkins University/Sidney Kimmel Cancer Center and University of Maryland/Greenebaum Cancer Center, to diverse medical fields at Johns Hopkins University, Johns Hopkins Hospital, and the University of Maryland.

Broadening Your Search: Nearby Options

While Baltimore offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Maryland. Cities with active trials include Bethesda (7 trials), Brooklyn (1 trial), Annapolis (1 trial), Glen Burnie (1 trial), Hunt Valley (1 trial), Towson (1 trial), and Cumberland (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 15 new trials launched this month, 15 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials include children, and 1 new trial is specifically designed for male participants. Academic institutions continue to play a vital role in Baltimore's research ecosystem, with Johns Hopkins University, University of Maryland, Baltimore, Johns Hopkins Bloomberg School of Public Health, and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsoring the majority of new trials. The VA Office of Research and Development and Bial R&D Investments, S.A. also contributed to new research efforts this month.

As we move further into spring, Baltimore's robust research community will continue to advance medical science through these diverse clinical trials, offering numerous ways for residents to contribute to health innovation.